PMID- 25599431
OWN - NLM
STAT- MEDLINE
DCOM- 20150331
LR  - 20150120
IS  - 1078-6791 (Print)
IS  - 1078-6791 (Linking)
VI  - 21
IP  - 1
DP  - 2015 Jan-Feb
TI  - The therapeutic effect and possible harm of puerarin for treatment of stage III 
      diabetic nephropathy: a meta-analysis.
PG  - 36-44
AB  - CONTEXT: Diabetic nephropathy (DN) is the main cause of end-stage kidney disease 
      in developed countries. Current therapy can slow the rate of progression of DN, 
      but eventually end-stage renal failure will occur in a proportion of patients. 
      Identification of new strategies and additional complementary and alternative 
      therapies for treating DN are important. OBJECTIVE: The research team wanted to 
      assess the beneficial and harmful effects of using puerarin plus angiotensin 
      converting enzyme inhibitor (ACEI) compared with using only ACEI for treatment of 
      individuals with stage III DN. DESIGN: The research team performed a 
      meta-analysis of randomized, controlled trials (RCTs) by searching the following 
      electronic databases: (1) the Cochrane Database of Systematic Reviews, (2) the 
      Cochrane Central Register of Controlled Trials (CENTRAL), (3) PubMed, (4) EMBASE 
      (Elsevier), (5) the Allied and Complementary Medicine Database (AMED), (6) the 
      Chinese Biomedicine Database (CBM), (7) the China National Knowledge 
      Infrastructure (CNKI), and (8) the Chinese Biomedical Journals (VIP), with no 
      language restrictions, as well as databases of clinical trials. OUTCOME MEASURES: 
      Measured outcomes included (1) urinary protein measured as urinary albumin 
      excretion rate (UAER) (mug/min) and 24-h urine protein (24-h UP) (mg/24 h); (2) 
      renal function measured as blood urea nitrogen (BUN) (mmol/L) and serum 
      creatinine (SCr) (mumol/L); (3) alpha1-microglobulin (alpha1-MG) (mg/24 h) and 
      endothelin-1 (ET-1) (ng/24 h); (4) end points (EPs); and (5) adverse events 
      (AEs). RESULTS: Ten RCTs involving 669 participants were included. All trials 
      were conducted and published in China. Treatment of DN with puerarin plus ACEI 
      significantly decreased the UAER-P < .0001, MD = -23.43 (95% CI, -33.95 to 
      -12.91), and had no effect on 24-h UP-P = .09, MD = -56.76 (95% CI, -122.65 to 
      9.12); BUN-P = .17, MD = -0.51 (95% CI, -1.24 to 0.21); and SCr-P = .26, MD = 
      -4.43 (95% CI, -12.05 to 3.20). One trial reported abdominal discomfort and 
      nausea (2 cases) in the treatment group. CONCLUSIONS: Puerarin may be a 
      beneficial therapy for treating DN; however, this hypothesis needs to be proven 
      by additional high-quality studies using large samples and multicenter evidence.
FAU - Wang, Bin
AU  - Wang B
FAU - Chen, Shibo
AU  - Chen S
FAU - Yan, Xiufeng
AU  - Yan X
FAU - Li, Mingdi
AU  - Li M
FAU - Li, Daqi
AU  - Li D
FAU - Lv, Pin
AU  - Lv P
FAU - Ti, Guixiang
AU  - Ti G
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PL  - United States
TA  - Altern Ther Health Med
JT  - Alternative therapies in health and medicine
JID - 9502013
RN  - 0 (Isoflavones)
RN  - 0 (Vasodilator Agents)
RN  - AYI8EX34EU (Creatinine)
RN  - Z9W8997416 (puerarin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Albuminuria
MH  - Blood Urea Nitrogen
MH  - Creatinine/blood
MH  - Diabetic Nephropathies/*drug therapy/epidemiology/physiopathology
MH  - Humans
MH  - Isoflavones/*adverse effects/*therapeutic use
MH  - Middle Aged
MH  - Vasodilator Agents/*adverse effects/*therapeutic use
EDAT- 2015/01/20 06:00
MHDA- 2015/04/01 06:00
CRDT- 2015/01/20 06:00
PHST- 2015/01/20 06:00 [entrez]
PHST- 2015/01/20 06:00 [pubmed]
PHST- 2015/04/01 06:00 [medline]
PST - ppublish
SO  - Altern Ther Health Med. 2015 Jan-Feb;21(1):36-44.